Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2019 2
2020 6
2021 2
2022 2
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ, van der Wouden CH, Manson LE, Abdullah-Koolmees H, Blagec K, Blagus T, Böhringer S, Cambon-Thomsen A, Cecchin E, Cheung KC, Deneer VH, Dupui M, Ingelman-Sundberg M, Jonsson S, Joefield-Roka C, Just KS, Karlsson MO, Konta L, Koopmann R, Kriek M, Lehr T, Mitropoulou C, Rial-Sebbag E, Rollinson V, Roncato R, Samwald M, Schaeffeler E, Skokou M, Schwab M, Steinberger D, Stingl JC, Tremmel R, Turner RM, van Rhenen MH, Dávila Fajardo CL, Dolžan V, Patrinos GP, Pirmohamed M, Sunder-Plassmann G, Toffoli G, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Swen JJ, et al. Lancet. 2023 Feb 4;401(10374):347-356. doi: 10.1016/S0140-6736(22)01841-4. Lancet. 2023. PMID: 36739136 Clinical Trial.
Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response.
Siamoglou S, Boers R, Koromina M, Boers J, Tsironi A, Chatzilygeroudi T, Lazaris V, Verigou E, Kourakli A, van IJcken WFJ, Gribnau J, Symeonidis A, Patrinos GP. Siamoglou S, et al. Hum Genomics. 2023 Apr 25;17(1):37. doi: 10.1186/s40246-023-00483-7. Hum Genomics. 2023. PMID: 37098643 Free PMC article.
Clinical implementation of preemptive pharmacogenomics in psychiatry.
Skokou M, Karamperis K, Koufaki MI, Tsermpini EE, Pandi MT, Siamoglou S, Ferentinos P, Bartsakoulia M, Katsila T, Mitropoulou C, Patrinos GP; Consortium of the PREPARE study in Greece. Skokou M, et al. Among authors: siamoglou s. EBioMedicine. 2024 Mar;101:105009. doi: 10.1016/j.ebiom.2024.105009. Epub 2024 Feb 16. EBioMedicine. 2024. PMID: 38364700 Free PMC article.
Identification and functional validation of novel pharmacogenomic variants using a next-generation sequencing-based approach for clinical pharmacogenomics.
Siamoglou S, Koromina M, Hishinuma E, Yamazaki S, Tsermpini EE, Kordou Z, Fukunaga K, Chantratita W, Zhou Y, Lauschke VM, Mushiroda T, Hiratsuka M, Patrinos GP. Siamoglou S, et al. Pharmacol Res. 2022 Feb;176:106087. doi: 10.1016/j.phrs.2022.106087. Epub 2022 Jan 13. Pharmacol Res. 2022. PMID: 35033648
Key Pharmacogenomic Considerations for Sickle Cell Disease Patients.
Kolliopoulou A, Stratopoulos A, Siamoglou S, Sgourou A, Ali BR, Papachatzopoulou A, Katsila T, Patrinos GP. Kolliopoulou A, et al. Among authors: siamoglou s. OMICS. 2017 Jun;21(6):314-322. doi: 10.1089/omi.2017.0058. Epub 2017 May 9. OMICS. 2017. PMID: 28486096
18 results